|D011655||Pulmonary Embolism NIH||0.26|
There is one clinical trial.
- There is a knowledge gap associated with the management of patients with COVID-19 lung injury and a laboratory picture compatible with disseminated intravascular coagulation (DIC). Clinical data to date support that COVID-19 is associated with a prothrombotic state that is not simply explained by an influx of more critically ill individuals. - These patients suffer from severe respiratory failure; hypoxemia and ventilator dependence are the primary concerns; ARDS with respiratory failure is frequently the cause of death. Macroscopic and probable microvascular thromboembolic events are a major concern in this population. - When DIC is associated with COVID-19, it predicts a very poor prognosis. - We plan to evaluate the clinical efficacy and safety of low-dose IV bolus tenecteplase (TNK) together with anticoagulation compared with control patients on therapeutic anticoagulation alone in hospitalized adults diagnosed with COVID-19 and acute intermediate-risk PE. We believe that acute PE in the setting of active COVID-19 infections likely portend a poor prognosis. - Prospective, multicenter, randomized two-arm trial enrolling consecutive patients who meet enrollment criteria. - We hope to generate evidence that low-dose TNK together with anticoagulation is beneficial in these patients.
Description: For example, a patient may start with a heart rate of 100/min and systolic BP of 100 mm Hg (shock index = 1) and after therapy, HR might be 90, with systolic BP of 110 mm Hg (shock index of 0.81), an improvement of 19%.Measure: Percent improvement in shock index (HR/SBP) 6 hours after the TNK/placebo bolus. Time: 6 hours post TNK/placebo infusion
Description: Assessment of patient status using an ordinal scale will be recorded at baseline and once daily in the morning while hospitalized.Measure: 1. Clinical status at 24 hours after administration of TNK / placebo based upon 7-point scale. Time: 24 +/- 6 hours post TNK/placebo infusion.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports